Title : Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models.

Pub. Date : 2018 Jun

PMID : 29526823






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The aim of this work was to test the efficacy of a complete EGFR-inhibition by osimertinib plus the monoclonal antibody cetuximab or the MEK1/2-inhibitor selumetinib in EGFR-mutated NCLC in vivo models. AZD 6244 epidermal growth factor receptor Homo sapiens
2 CONCLUSIONS: We showed that a dual vertical EGFR blockade with osimertinib plus selumetinib/cetuximab is a novel effective therapeutic option in EGFR-mutated NCLC and that hedgehog pathway activation and its interplay with MAPK is involved in resistance to these combination treatments. AZD 6244 epidermal growth factor receptor Homo sapiens